Breast Cancer Clinical Trials in Cleveland

Showing 41-60 of 356 trials

Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast

NCT06129747

The standard treatment for participants whose cancer has returned after breast conserving surgery is radiation given twice daily (separated by at least 6 hours) for a total of 30 treatments. The purpose of this study is to find out if giving radiation once a day for 15 treatments after repeat breast conserving surgery works as well as giving it the standard way.

Breast CancerTumor, Breast

Case Comprehensive Cancer Center55 participantsStarted Nov 2023

Cleveland, Ohio, United States • Cleveland, Ohio, United States

COMPLETEDPHASE3< 1 mile

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

NCT00066690

RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known whether suppression of ovarian function plus either tamoxifen or exemestane is more effective than tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer. PURPOSE: This randomized phase III trial studies ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer.

Estrogen Receptor Positive Breast CancerProgesterone Receptor Positive TumorRecurrent Breast Carcinoma+5 more

ETOP IBCSG Partners Foundation3,066 participantsStarted Dec 2003

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Scottsdale, Arizona, United States +497 more locations

Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Breast Cancer Trials in Other Cities

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

A Study of MGC026 in Participants With Advanced Solid Tumors

EXoPERT EMERALD Clinical Study

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Phase III Study of 5tx vs 15tx of RT (X-rays or Protons) Including RNI in Breast Cancer Patients

Other Conditions in Cleveland